Coagulation Dysfunctions: A Hallmarks for Thrombo-Inflammatory Risks in SARS-CoV-2 Hospitalized Patients
Latin American Journal of Pharmacy
; 41(2):357-363, 2022.
Article
in English
| EMBASE | ID: covidwho-1976051
ABSTRACT
The relevance of coagulation malfunction in COVID-19 (severe coronavirus disease) is ambiguous. Current study aimed to assess the coagulation among SARS-CoV-2 hospitalized patients. A cross sectional study with qualitative approach was conducted among 300 patients who are already diagnosed as COVID 19 compared to 300 apparently healthy control group attended to Red Sea State during study period from April 2020 to April 2021. The Humaclot Due Plus1 coagulation analyser was used to estimate the prothrombin time (PT), activated partial prothrombin time (APTT), and international normalized ratio (INR) (Wiesbaden 1, Germany), adding 25 μL of plasma in cuvette. The study result showed that in COVID-19 patients D.dimer level is high (2000-10000 ng/mL) compared with control group (up to 500 ng/mL). COVID-19 infection cause high D. dimer level which can lead to thrombosis event or bleeding tendency. Abnormal coagulation results were revealed among SARS-CoV-2, with markedly elevated D. dimer.
adult; article; bleeding tendency; blood clotting disorder; coagulation analyzer; controlled study; coronavirus disease 2019; cross-sectional study; cuvette; disseminated intravascular clotting; female; Germany; hospital patient; human; human tissue; international normalized ratio; major clinical study; male; nonhuman; prothrombin time; Red Sea; risk assessment; Severe acute respiratory syndrome coronavirus 2; thrombosis; blood clotting factor 8 concentrate; D dimer; dimer
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Latin American Journal of Pharmacy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS